This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXNPEB7Q0U9_M.jpg
Orbimed Advisors’s holding in Adicet Bio, Inc. increased to about 5.5 million shares with the purchase.
Orbimed Advisors first bought Adicet Bio, Inc. stock in the first quarter of 2018. Orbimed Advisors also owns Bristol-Myers Squibb Co (NYSE:BMY), Merck (MRK), Mirati Therapeutics Inc (NASDAQ:MRTX) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX). Adicet Bio, Inc. is its number eleven position by number of shares and market value among biotechnology & life sciences stocks.
In contrast, California State Teachers Retirement System, Millennium Management, and Victory Capital Management sold all their ACET shares.
Orbimed Advisors has also recently reduced their share in Alector, Inc. (NASDAQ:ALEC). The total value of the shares sold is estimated at around $105 million.
In addition, Orbimed Advisors increased their share in Alpine Immune Sciences, Inc. (NASDAQ:ALPN) and TELA Bio, Inc. (NASDAQ:TELA). The total value of the shares bought is estimated at around $2 million.
Orbimed Advisors also reduced their share in ESSA Pharma Inc . (NASDAQ:EPIX) and 89bio, Inc. (NASDAQ:ETNB). The total value of the shares sold is estimated at around $54 million.
Additionally, Orbimed Advisors established new holdings in Fusion Pharmaceuticals Inc. (FUSN). The total value of the shares bought is estimated at around $52 million.
